Skip to main content

Table 1 Characteristics of patients with rheumatoid arthritis in the two treatment groups

From: Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

  Treatment
Patients Infliximab Etanercept
No. 32 17
Age (years)a 56.7 (23.5–80.9) 55.3 (23.2–70.4)
Female/male 25/7 10/7
Duration of disease (years)a 12.9 (3.0–55.5) 13.7 (2.5–41.0)
Serum CRP at baseline (mg/l)a 20 (1–84) 36 (1–85)
Serum COMP at baseline (u/l)a 11.3 (5.5–19.2) 12.2 (8.1–29.7)
DAS28 at baselinea 5.3 (2.4–8.1) 5.9 (3.7–7.5)
HAQ at baselinea 1.4 (0.4–2.8) 1.6 (0.3–2.8)
Monotherapy/combination therapy 5/27   3/14
Prednisolone/no prednisolone 20/12 11/6
ACR20 response at 3 months 16 (50%) 11 (65%)
  1. There were no significant differences between the groups. aMedian (range). ACR20 = 20% improvement according to the American College of Rheumatology criteria; CRP = C-reactive protein; COMP = cartilage oligomeric matrix protein; DAS = disease activity score; HAQ = health assessment questionnaire.